Literature DB >> 9435432

A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo.

N A Huizenga1, J W Koper, P De Lange, H A Pols, R P Stolk, H Burger, D E Grobbee, A O Brinkmann, F H De Jong, S W Lamberts.   

Abstract

We investigated whether a polymorphism at nucleotide position 1220, resulting in an asparagine-to-serine change at codon 363 in the glucocorticoid receptor (GR) gene is associated with an altered sensitivity to glucocorticoids. In a group of 216 elderly persons, 13 heterozygotes for the N363S polymorphism were identified by PCR/single strand conformation polymorphism analysis. In 2 dexamethasone (DEX) suppression tests (DSTs), using 1 and 0.25 mg DEX, the circulating cortisol and insulin concentrations were compared between N363S carriers and controls. In the 1-mg DST, there were no differences between N363S carriers and controls, with respect to adrenal suppression, but there was a significantly higher (P < 0.05) insulin response in N363S carriers. In the 0.25-mg DST, a significantly larger (P < 0.05) cortisol suppression and higher (P < 0.05) insulin response were seen in N363S carriers. Comparison of blood pressure, body mass index (BMI), and bone mineral density (BMD) between the N363S carriers and controls showed that N363S carriers had a higher (P < 0.05) BMI but normal blood pressure. There was an obvious trend towards lower age-, BMI-, and sex-adjusted BMD in the lumbar spine in N363S carriers. GR characteristics measured in 41 controls and 9 N363S carriers in peripheral mononuclear leucocytes showed no differences between N363S carriers and controls, with respect to GR number and ligand binding affinity. However, there was a trend towards greater sensitivity to DEX in the carriers' lymphocytes, in a mitogen-induced cell proliferation assay. In transfection assays, the capacity of the codon 363 variant to activate mouse mammary tumor virus promotor-mediated transcription in COS-1 cells was unaltered, when compared with the wild-type GR. We conclude that in 6.0% of our study population, a polymorphism in codon 363 of the GR gene was found. Individuals carrying this polymorphism seemed healthy at clinical examination but had a higher sensitivity to exogenously administered glucocorticoids, with respect to both cortisol suppression and insulin response. Life-long exposure to the mutated allele may be accompanied by an increased BMI and a lowered BMD in the lumbar spine but does not affect blood pressure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9435432     DOI: 10.1210/jcem.83.1.4490

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  107 in total

1.  High penetrance, overweight, and glucocorticoid receptor variant: case-control study.

Authors:  R C Lin; W Y Wang; B J Morris
Journal:  BMJ       Date:  1999-11-20

2.  Tsp509I polymorphism in exon 2 of the glucocorticoid receptor gene in relation to obesity and cortisol secretion: cohort study.

Authors:  R Rosmond; C Bouchard; P Björntorp
Journal:  BMJ       Date:  2001-03-17

Review 3.  Pharmacogenetics of asthma.

Authors:  A Fenech; Ian P Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

Review 4.  Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome.

Authors:  P Putignano; F Pecori Giraldi; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

Review 5.  Corticosteroid receptor genetic polymorphisms and stress responsivity.

Authors:  Roel DeRijk; E Ronald de Kloet
Journal:  Endocrine       Date:  2005-12       Impact factor: 3.633

6.  Glucocorticoid receptor polymorphisms in inflammatory bowel disease.

Authors:  G Decorti; S De Iudicibus; G Stocco; S Martelossi; I Drigo; F Bartoli; A Ventura
Journal:  Gut       Date:  2006-07       Impact factor: 23.059

Review 7.  Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.

Authors:  J A P Da Silva; J W G Jacobs; J R Kirwan; M Boers; K G Saag; L B S Inês; E J P de Koning; F Buttgereit; M Cutolo; H Capell; R Rau; J W J Bijlsma
Journal:  Ann Rheum Dis       Date:  2005-08-17       Impact factor: 19.103

8.  Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia.

Authors:  Mariël L te Winkel; Robert D van Beek; Sabine M P F de Muinck Keizer-Schrama; André G Uitterlinden; Wim C J Hop; Rob Pieters; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

Review 9.  The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease.

Authors:  A Sasha Tait; Cherie L Butts; Esther M Sternberg
Journal:  J Leukoc Biol       Date:  2008-07-29       Impact factor: 4.962

10.  Glucocorticoid receptor gene variant in the 3' untranslated region is associated with multiple measures of blood pressure.

Authors:  Charles C Chung; Lawrence Shimmin; Sivamani Natarajan; Craig L Hanis; Eric Boerwinkle; James E Hixson
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.